

MSCA-ITN-2017 – Innovative Training Networks



Bio-orthogonal catalysis for cancer therapy

Coordinator's report

Mid-Term Check Meeting

Edinburgh, June 5th 2019



TITLE: *Bio-orthogonal catalysis for cancer therapy*

ACRONYM: *THERACAT*

DURATION: *01/03/2018 – 28/02/2022 (4 years project)*

PROJECT ID: *765497*

FUNDED UNDER: *H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers*

TOPIC: *MSCA-ITN-2017 - Innovative Training Networks*

FUNDING SCHEME: *MSCA-ITN-ETN - European Training Networks*

USEFUL WEBSITES:

- CORDIS Web: <https://cordis.europa.eu/project/rcn/215989/factsheet/en>
- THERACAT Web: www.theracat.eu/
- THERACAT Intranet: <https://theracat.eu/wp-login.php>

CONFIDENTIAL FILES

RELEVANT DOCUMENTS (Available on the intranet):

- GRANT AGREEMENT (GA, Declaration of Honour, Data sheet)
- CONSORTIUM AGREEMENT



Bio-orthogonal catalysis for cancer therapy

Recruitment report

Mid-Term Check Meeting

Edinburgh, June 5th 2019

THERACAT Recruitment: open, transparent, international, competitive, and based on an equal opportunity policy

- ✓ [European Charter for Researchers](#)
- ✓ [Code of Conduct for the Recruitment of Researchers](#)



HR EXCELLENCE IN RESEARCH

RECRUITMENT PLAN

- Approved: Kick-off Meeting (Supervisory Board & Recruitment Comm.) – MS1
- Step-by-step guide:
 - ✓ The Recruitment Committee: members and responsibilities
 - ✓ Eligibility criteria for ESRs
 - ✓ Recruitment procedure:
 - Job Description: defining the advertised roles, equal opportunities, other obligations towards recruited researchers
 - Advertising the positions: EURAXESS and international publication of vacancies in other websites
 - Candidate selection: selection panel, interview selection format, references
 - Successful candidates: Researcher Declarations, employment contract, domestic issues
 - ✓ Templates for: (1) Job description; (2) Interview Assessment; (3) Minutes of the selection process

Templates: Recruitment Plan

ANNEX 2. Interview Assessment (Template)

Evaluator Name		Dept/Division	
Candidate name		Interview Date	

EVALUATION OF THE ACADEMIC RECORD (0-25)

Observations:	
Score	

EVALUATION OF THE EXPERIENCE (0-25)

Observations:	
Score	

EVALUATION OF THE MERITS (0-25)

Observations:	
Score	

INTERVIEW - If necessary (0-25)

Observations:	
Score	

TOTAL SCORE (0-100):

Signature _____

ANNEX 3. Minutes of the selection process (Template)

MINUTES OF THE SELECTION PROCESS FOR THE SELECTION OF ESRs

Project: THERACAT
 Beneficiary: XXX
 ESR number: ESRX
 Date: dd/mm/yyyy

Evaluators:

- YYY from XXX
- YYY from XXX
- YYY from XXX

The final prioritized ESR candidate list:

CANDIDATE	ACADEMIC	EXPERIENCE	MERITS	INTERVIEW	TOTAL

Note: Scores obtained in the selection process.

Signed by XXXX	Signed by XXXX	Signed by XXXX
-------------------	-------------------	-------------------

JOB OFFERS

- Recruitment performed individually by each beneficiary ↔ HR teams
- All positions advertised internationally:
 - ✓ ESR1: <https://euraxess.ec.europa.eu/jobs/322936>
 - ✓ ESR2: <https://euraxess.ec.europa.eu/jobs/322708>
 - ✓ ESR3: <https://euraxess.ec.europa.eu/jobs/325162>
 - ✓ ESR4: <https://euraxess.ec.europa.eu/jobs/321889>
 - ✓ ESR5: <https://euraxess.ec.europa.eu/jobs/333581>
 - ✓ ESR6: <https://euraxess.ec.europa.eu/jobs/321888>
 - ✓ ESR7: <https://euraxess.ec.europa.eu/jobs/318985>
 - ✓ ESR8: <https://euraxess.ec.europa.eu/jobs/355274>
 - ✓ ESR9: <https://euraxess.ec.europa.eu/jobs/334185>
 - ✓ ESR10: <https://euraxess.ec.europa.eu/jobs/313142>
 - ✓ ESR11: <https://euraxess.ec.europa.eu/jobs/332500>
 - ✓ ESR12: <https://euraxess.ec.europa.eu/jobs/327795>
 - ✓ ESR13: <https://euraxess.ec.europa.eu/jobs/323035>

APPLICATIONS RECEIVED & INTERVIEWS

- Applications: 467 candidates → **35.9 applications/position**
- Interviews: 64 candidates → **4.9 interviews/position**

Position	Institution	Applications received		Candidates interviewed		ESR selected
		Female	Male	Female	Male	Gender
ESR1	GRO ¹	9	15	1	1	Female
ESR2	TAU	2	6	2	4	Male
ESR3	TEVA	0	12	0	3	Male ²
ESR4	TUE ³	17	28	2	3	Female
ESR5	EDI	10	8	1	2	Male
ESR6	TUE	33	50	1	1	Male
ESR7	IBEC	17	20	3	0	Female
ESR8	TUE ³	17	28	2	3	Female
ESR9	BGX	27	34	3	4	Female
ESR10	BAS	6	34	1	1	Male
ESR11	EDI	7	5	2	0	Female
ESR12	TAG	26	34	7	4	Female
ESR13	TAU	7	15	6	7	Male

(1) 4 candidates were invited for interview, but 2 declined because they had already accepted positions elsewhere. (2) ESR3 is already selected and only pending the signature of his contract. (3) Two descriptions were made for Euraxess but for the selection TUE made no distinction between the two, given the high similarity in the requirements for the candidates for both positions (numbers refer to the total for the 2 positions, ESR4 and ESR8).

SELECTED ESRs

Position	Institution	Name	Gender	Country	Start date
ESR1	GRO	Michela Vargiu	Female	IT	01/01/19
ESR2	TAU	Shreyas Wagle	Male	IN	21/11/18
ESR3	TEVA	Krishna Vippala	Male	IN	Pending
ESR4	TUE	Anjana Sathyan	Female	IN	01/01/19
ESR5	EDI	Stephen Croke	Male	IE	12/11/18
ESR6	TUE	Emmanouil Archontakis	Male	EL	01/03/19
ESR7	IBEC	Rodica Alis Olea	Female	RO	16/10/18
ESR8	TUE	Linlin Deng	Female	CN	11/03/19
ESR9	BGX	Africa Galvez Flores	Female	ES	14/01/19
ESR10	BAS	Boris Lozhkin	Male	RU	01/12/18
ESR11	EDI	Melissa van de l'Isle	Female	NL	01/02/19
ESR12	TAG	Maria Vlastara	Female	EL	15/01/19
ESR13	TAU	Daniel Rodriguez	Male	ES	09/12/18

Gender-balanced
distribution



54% 46%



ESR1




ESR2



ESR3



ESR4



ESR5



ESR6



ESR7



ESR8



ESR9



ESR10



ESR11



ESR12



ESR13

RESEARCHER DECLARATION (RD)

- Mandatory by the EC (Art. 19 of the GA)
- Any new employment contract for the existing researcher requires a new RD.
- In case of any change in the employment contract (long sick leaves, maternity/parental leave, etc.), the RD should be updated.
- Already submitted by each beneficiary for all recruited researchers (*ESR3 pending*):

Fellow Id	First Name	Last Name	Gender
1	Rodica Alis	Olea	Female
2	Shreyas	Wagle	Male
3	Boris	Lozhkin	Male
4	Michela	Vargiu	Female
5	Africa	Galvez Flores	Female
6	Maria	Vlastara	Female
7	Melissa	van de L'Isle	Female
8	Stephen	Croke	Male
9	Linlin	Deng	Female
10	Anjana	Sathyan	Female
11	Daniel	Rodriguez	Male
12	Emmanouil	Archontakis	Male

MODIFICATIONS FROM ORIGINAL PLAN

- **Some ESRs incorporated later (visa issues)** → all before M12 (except ESR8, 10-days delay)
- **ESR3 (TEVA):** pending TAU-TEVA contract completion
 - ✓ Ensure fellow's enrolment at TAU PhD Programme (ITN good practices)
 - ✓ First time TEVA Israel participates in an ITN project (regulation of internal issues needed)
 - ✓ No previous experience at TAU of PhD student conducting research in industrial company → bureaucratic steps and agreements required (mediated by Dr. Amir and Dr. Avramovitch, working intensively to accelerate process & comply internal regulations)
 - ✓ Current status:
 - Visa already issued
 - Finalising to formalise all aspects between TAU and TEVA
 - Incorporation expected within next few weeks
- **ESR6 (TUE):** relocation from IBEC to TUE
 - ✓ Dr. Albertazzi double appointment IBEC-TUE
 - ✓ TUE substantial investment in microscopy
 - ✓ Amendment approved by EC

STRATEGY FOR DEALING WITH SCIENTIFIC MISCONDUCT

- Guide for dealing with scientific misconduct within the project – MS1
- Read and agreed by all supervisors and ESRs



Contents

1. Purpose and scope	3
1.1 Purpose.....	3
1.2 Scope	3
2. THERACAT Strategy.....	4
2.1 Prevention	4
2.2 Dealing with scientific misconduct.....	5
2.3 Sanctions	5
ANNEX 1. The European Code of Conduct for Research Integrity	7
ANNEX 2. Agreement on the strategy for dealing with scientific misconduct (Template).....	8



Bio-orthogonal catalysis for cancer therapy

Deliverables

Mid-Term Check Meeting

Edinburgh, June 5th 2019

DELIVERABLES (Art. 19 of the GA):

- To be uploaded directly to the “Funding & Tenders” Portal by the Coordinator.
- All deliverables have been / will be also uploaded on the THERACAT intranet.
- Scientific deliverables and other deliverables as defined in the GA Annex 1.
- In case of an update of a deliverable, the PO needs to be notified and re-opens the session.
- Procedure:
 - Template available on the THERACAT intranet.
 - Coordinator will inform deliverable’s leader 2 months before the deadline.
 - Reviewed by other project members and the coordinator before submission.

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	<i>Under revision</i>
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	<i>Under revision</i>
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	<i>Under revision</i>
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	<i>Under revision</i>
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	<i>Under revision</i>
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	<i>Under revision</i>
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	<i>Under revision</i>
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	<i>Under revision</i>
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	<i>Under revision</i>
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	<i>Under revision</i>
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	<i>Under revision</i>
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	<i>Under revision</i>
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24: imminent submission

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion			5/2019	Other	MGT	Under revision
D7.2	7	Training events minutes			5/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)			5/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	10/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

Deadline:
30/06/2019

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24: M18

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)			5/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)			5/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A

Deadline:
31/08/2019

SCIENTIFIC & MANAGEMENT DELIVERABLES M01-M24: M19-M24

#	WP	TITLE	LEADER	MONTH	STATUS	TYPE	RTD OR MGT	APPROVAL
D2.1	2	Network Meetings minutes (kick-off)	IBEC	1	13/08/2018	Report	MGT	Approved
D2.2	2	Consortium Agreement	IBEC	2	28/02/2019	Report	MGT	Under revision
D2.3	2	Supervisory Board of the network	IBEC	2	14/08/2018	Other	MGT	Approved
D8.1	8	Website completion	EDI	6	19/09/2018	Website, etc.	MGT	Under revision
D7.1	7	Personal Career Development Plans	IBEC	10	14/05/2019	Report	MGT	Under revision
D1.1	1	A - Requirement No. 1	IBEC	12	10/05/2019	Ethics	RTD	Under revision
D1.2	1	NEC - Requirement No. 2	IBEC	12	06/03/2019	Ethics	RTD	Under revision
D1.3	1	HCT - Requirement No. 3	IBEC	12	18/03/2019	Ethics	RTD	Under revision
D2.4	2	Network Meetings minutes (Meeting 1)	IBEC	12	17/05/2019	Report	MGT	Under revision
D2.5	2	Recruitment completion	TU/e	12	20/05/2019	Other	MGT	Under revision
D7.2	7	Training events minutes	TAU	12	17/05/2019	Report	MGT	Under revision
D7.3	7	ESRs periodic short reports and AC recommendations (M12)	IBEC	12	17/05/2019	Report	MGT	Under revision
D8.2	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)	EDI	12	20/05/2019	Report	MGT	Under revision
D2.6	2	Progress Report	IBEC	13	17/05/2019	Report	MGT	Under revision
D3.1	3	Novel metal complexes for bio-orthogonal catalysis	GRO	16	PENDING	Report	RTD	N/A
D4.1	4	Library of anticancer prodrugs	EDI	16	PENDING	Report	RTD	N/A
D5.1	5	Library of targeted catalysts carriers	TU/e	18	PENDING	Report	RTD	N/A
D6.1	6	Set of mCherry-labeled orthotopic models of cancer in mice	TAU	18	PENDING	Report	RTD	N/A
D7.4	7	Training events minutes (Training event 2)	TAU	18	PENDING	Report	MGT	N/A
D7.5	7	ESRs periodic short reports and AC recommendations (M18)	IBEC	18	PENDING	Report	MGT	N/A
D6.2	6	Results of the biocompatibility tests for the catalysts	TAU	22	PENDING	Report	RTD	N/A
D2.7	2	Network Meetings minutes (Meeting 2)	IBEC	24	PENDING	Report	MGT	N/A
D7.6	7	Training events minutes (Training event 3)	TAU	24	PENDING	Report	MGT	N/A
D7.7	7	ESRs periodic short reports and AC recommendations (M24)	IBEC	24	PENDING	Report	MGT	N/A
D7.8	7	Updated Personal Career Development Plans (M24)	IBEC	24	PENDING	Report	MGT	N/A
D8.3	8	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24)	EDI	24	PENDING	Report	MGT	N/A
D8.4	8	THERACAT video	IBEC	24	PENDING	Website, etc.	MGT	N/A



Bio-orthogonal catalysis for cancer therapy

Milestones

Mid-Term Check Meeting

Edinburgh, June 5th 2019

MILESTONES (Art. 20.3 of the GA):

- To be reported to the PO. Status of milestones will be updated on project intranet.
- Procedure:
 - Coordinator will inform milestone's leader 2 months before the deadline.
 - **If milestone not achieved, review contingency plans & alternatives.**

SCIENTIFIC & MANAGEMENT MILESTONES M01-M24:

#	WP	TITLE	LEADER	MONTH	STATUS	MEANS OF VERIFICATION
MS1	2	Guidelines for recruitment and assessment of ESRs, PCDPs, strategy for dealing with scientific misconduct	IBEC	4	21/08/2018	Guidelines available to all partners and approved by SB
MS2	7	Assessment Commissions	IBEC	6	01/09/2018	AC designated and operative
MS3	8	Intranet and extranet website	EDI	6	12/09/2018	Tool completed and functional
MS4	2, 7	ESRs Recruitment and PCDPs	IBEC	12	Pending ESR3	Employment contracts and agreement on the strategy for dealing with scientific misconduct properly signed and PCDPs ready for all ESRs
MS5	7	ESR local doctoral studies	IBEC	12	Pending ESR3	All ESRs accepted and enrolled in the corresponding doctoral programme
MS6	2	Project Check	IBEC	14	Current meeting	Meeting between REA and consortium
MS7	4	Synthesis of the first prodyne	IBEC	18	PENDING	Spectroscopic characterization
MS8	3	Synthesis of the first catalyst	GRO	18	PENDING	Spectroscopic characterization and activity test
MS9	4	Synthesis of the first prodrug	EDI	18	PENDING	Spectroscopic characterization
MS10	5	Establishments of the protocol for super resolution imaging in cells	IBEC	18	PENDING	Image resolution analysis
MS11	6	Establishments of the protocol for in vivo cancer imaging	TAG	18	PENDING	Image analysis
MS12	3	First catalyst supported on a nanoparticle	TU/e	21	PENDING	Spectroscopic characterization
MS13	6	Establishment of an mCherry orthotopic cancer model	TAU	21	PENDING	Histology
MS14	2	Midterm project assessment	IBEC	24	PENDING	Project follows as planned
MS15	8	Midterm dissemination and outreach activities assessment	TAU	24	PENDING	Number and quality of publications, conferences attended, outreach activities conducted
MS16	5	Synthesis and evaluation of the first cell-targeted nanocarrier	TU/e	24	PENDING	Cell targeting experiments

SCIENTIFIC & MANAGEMENT MILESTONES M01-M24: already reached

#	WP	TITLE	LEADER	MONTH	STATUS	MEANS OF VERIFICATION
MS1	2	Guidelines for recruitment and assessment of ESRs, PCDPs, strategy for dealing with scientific misconduct	IBEC	4	21/08/2018	Guidelines available to all partners and approved by SB
MS2	7	Assessment Commissions	IBEC	6	01/09/2018	AC designated and operative
MS3	8	Intranet and extranet website	EDI	6	12/09/2018	Tool completed and functional
MS4	2, 7	ESRs Recruitment and PCDPs	IBEC	12	<i>Pending ESR3</i>	Employment contracts and agreement on the strategy for dealing with scientific misconduct properly signed and PCDPs ready for all ESRs
MS5	7	ESR local doctoral studies	IBEC	12	<i>Pending ESR3</i>	All ESRs accepted and enrolled in the corresponding doctoral programme
MS6	2	Project Check	IBEC	14	<i>Current meeting</i>	Meeting between REA and consortium
MS7	4	Synthesis of the first prodyne	IBEC	18	PENDING	Spectroscopic characterization
MS8	3	Synthesis of the first catalyst	GRO	18	PENDING	Spectroscopic characterization and activity test
MS9	4	Synthesis of the first prodrug	EDI	18	PENDING	Spectroscopic characterization
MS10	5	Establishments of the protocol for super resolution imaging in cells	IBEC	18	PENDING	Image resolution analysis
MS11	6	Establishments of the protocol for in vivo cancer imaging	TAG	18	PENDING	Image analysis
MS12	3	First catalyst supported on a nanoparticle	TU/e	21	PENDING	Spectroscopic characterization
MS13	6	Establishment of an mCherry orthotopic cancer model	TAU	21	PENDING	Histology
MS14	2	Midterm project assessment	IBEC	24	PENDING	Project follows as planned
MS15	8	Midterm dissemination and outreach activities assessment	TAU	24	PENDING	Number and quality of publications, conferences attended, outreach activities conducted
MS16	5	Synthesis and evaluation of the first cell-targeted nanocarrier	TU/e	24	PENDING	Cell targeting experiments

SCIENTIFIC & MANAGEMENT MILESTONES M01-M24: imminent delivery

#	WP	TITLE	LEADER	MONTH	STATUS	MEANS OF VERIFICATION
MS1	2	Guidelines for recruitment and assessment of ESRs, PCDPs, strategy for dealing with scientific misconduct	IBEC	4	21/08/2018	Guidelines available to all partners and approved by SB
MS2	7	Assessment Commissions	IBEC	6	01/09/2018	AC designated and operative
MS3	8	Intranet and extranet website	EDI	6	12/09/2018	Tool completed and functional
MS4	2, 7	ESRs Recruitment and PCDPs	IBEC	12	Pending ESR3	Employment contracts and agreement on the strategy for dealing with scientific misconduct properly signed and PCDPs ready for all ESRs
MS5	7	ESR local doctoral studies	IBEC	12	Pending ESR3	All ESRs accepted and enrolled in the corresponding doctoral programme
MS6	2	Project Check	IBEC	14	Current meeting	Meeting between REA and consortium
MS7	4	Synthesis of the first prodyne	IBEC	18	PENDING	Spectroscopic characterization
MS8	3	Synthesis of the first catalyst	GRO	18	PENDING	Spectroscopic characterization and activity test
MS9	4	Synthesis of the first prodrug	EDI	18	PENDING	Spectroscopic characterization
MS10	5	Establishments of the protocol for super resolution imaging in cells	IBEC	18	PENDING	Image resolution analysis
MS11	6	Establishments of the protocol for in vivo cancer imaging	TAG	18	PENDING	Image analysis
MS12	3	First catalyst supported on a nanoparticle	TU/e	21	PENDING	Spectroscopic characterization
MS13	6	Establishment of an mCherry orthotopic cancer model	TAU	21	PENDING	Histology
MS14	2	Midterm project assessment	IBEC	24	PENDING	Project follows as planned
MS15	8	Midterm dissemination and outreach activities assessment	TAU	24	PENDING	Number and quality of publications, conferences attended, outreach activities conducted
MS16	5	Synthesis and evaluation of the first cell-targeted nanocarrier	TU/e	24	PENDING	Cell targeting experiments

SCIENTIFIC & MANAGEMENT MILESTONES M01-M24: M18-M24

#	WP	TITLE	LEADER	MONTH	STATUS	MEANS OF VERIFICATION
MS1	2	Guidelines for recruitment and assessment of ESRs, PCDPs, strategy for dealing with scientific misconduct	IBEC	4	21/08/2018	Guidelines available to all partners and approved by SB
MS2	7	Assessment Commissions	IBEC	6	01/09/2018	AC designated and operative
MS3	8	Intranet and extranet website	EDI	6	12/09/2018	Tool completed and functional
MS4	2, 7	ESRs Recruitment and PCDPs	IBEC	12	<i>Pending ESR3</i>	Employment contracts and agreement on the strategy for dealing with scientific misconduct properly signed and PCDPs ready for all ESRs
MS5	7	ESR local doctoral studies	IBEC	12	<i>Pending ESR3</i>	All ESRs accepted and enrolled in the corresponding doctoral programme
MS6	2	Project Check	IBEC	14	<i>Current meeting</i>	Meeting between REA and consortium
MS7	4	Synthesis of the first prodyne	IBEC	18	PENDING	Spectroscopic characterization
MS8	3	Synthesis of the first catalyst	GRO	18	PENDING	Spectroscopic characterization and activity test
MS9	4	Synthesis of the first prodrug	EDI	18	PENDING	Spectroscopic characterization
MS10	5	Establishments of the protocol for super resolution imaging in cells	IBEC	18	PENDING	Image resolution analysis
MS11	6	Establishments of the protocol for in vivo cancer imaging	TAG	18	PENDING	Image analysis
MS12	3	First catalyst supported on a nanoparticle	TU/e	21	PENDING	Spectroscopic characterization
MS13	6	Establishment of an mCherry orthotopic cancer model	TAU	21	PENDING	Histology
MS14	2	Midterm project assessment	IBEC	24	PENDING	Project follows as planned
MS15	8	Midterm dissemination and outreach activities assessment	TAU	24	PENDING	Number and quality of publications, conferences attended, outreach activities conducted
MS16	5	Synthesis and evaluation of the first cell-targeted nanocarrier	TU/e	24	PENDING	Cell targeting experiments

RESEARCH

RES. MGT.



Bio-orthogonal catalysis for cancer therapy

Ethical issues

Mid-Term Check Meeting

Edinburgh, June 5th 2019

ETHICS REQUIREMENTS (WP1)

During the project negotiation phase, several ethical issues were identified within the “Ethics Summary Report” that required specific attention: (1) Animals, (2) Third countries, (3) Human cells/tissues.

- All participants of the project are aware that the project has ethical issues associated and are committed to ensure that all planned activities and experiments are in conformance with national and EU legislation, regulations and ethical standards
- All fundamental ethical codes will be respected, periodically assessed and performed following the basic ethical principles described in the “Charter of Fundamental Rights” of the European Union (2000/C 364/01, 2010/C 83/02)

(1) Animals

- **Requirements:**
 - ✓ Copies of relevant authorisations (for breeders, suppliers, users, and facilities) for animal experiments must be obtained, kept in the file and submitted to the REA upon request.
 - ✓ Copy of ethical approvals (covering also the work with genetically-modified animals, if applicable) must be obtained, kept on the file and submitted to the REA upon request.
 - ✓ If applicable, copies of training certificates/personal licenses of the staff involved in animal experiments must be kept in the file and submitted to the REA upon request.
- **Partners involved:** TAU (Prof. Satchi-Fainaro), TAG (Dr. Robillard)
- **Compliance & details:** Deliverable 1.1 **(submitted)**
 - ✓ TAU:
 - Approval obtained from “Institutional Animal Care and Use Committee”
 - Animal experiments to be conducted by ESR13 (Daniel Rodríguez)
 - ✓ TAG:
 - Approval obtained from “Animal Welfare Committee of the Radboud University”
 - Animal experiments to be conducted by animal facilities’ technicians

(2) Third countries

- **Requirements:**

The applicant must confirm that the ethical standards and guidelines of Horizon2020 will be rigorously applied, regardless of the country in which the research is carried out. The applicant must confirm that the research performed outside the EU is compatible with the Union, national and international legislation and could have been legally conducted in one of the EU Member States.

- **Partners involved:** BAS (Prof. Ward), TAU (Prof. Satchi-Fainaro, Prof. Amir), TEVA (Dr. Avramovitch)
- **Compliance & details:** Deliverable 1.2 **(submitted)**
 - ✓ Research conducted will rigorously comply with the ethical standards and guidelines of Horizon2020 regardless of the country
 - ✓ Research conducted at Universität Basel (Switzerland), Tel Aviv University and TEVA Pharmaceutical Industries Ltd. (both located in Israel) is compatible with the Union, national and international legislation

(3) Human cells/tissues

- **Requirements:**

In case of use of human cells/tissues available commercially, details on cells/tissues type and provider must be submitted.

- **Partners involved:** IBEC (Dr. Albertazzi), TUE (Prof. Palmans), BAS (Prof. Ward), EDI (Prof. Unciti-Broceta), BGX (Dr. Goldie), TAU (Prof. Satchi-Fainaro), TAG (Dr. Robillard)
- **Compliance & details:** Deliverable 1.3 **(submitted)**
 - ✓ All samples of human origin to be used in the project are cells that are commercially available
 - ✓ Links to the providers included in D1.3
 - ✓ The project does not plan to use human embryonic stem cells, human cloning, or procedures where humans could be involved at all



Bio-orthogonal catalysis for cancer therapy

Management meetings

Mid-Term Check Meeting

Edinburgh, June 5th 2019

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

NETWORK MEETINGS

- **Progress monitoring** of the Network (short presentations by ESR fellows).
- Evaluation of scientific progress by Supervisory Board.
- **Assessment Commissions:** evaluate individual scientific and training progress of ESRs.
- Meetings will be responsibility of the host institution.
- Network Meetings will coincide with Training Events.
- Meetings shall be convened by the Coordinator with at least 45 days prior notice.
- Minutes of Meetings will be prepared by the Project Manager (15 days for approval).

KICK-OFF MEETING

- IBEC (Barcelona, Spain): May 31st, 2018
- Attended by: PIs
- Agenda:

Consortium Management		
10:00-10:30	Tea and Coffee.	
10:30-10:45	Roundtable introductions.	All
10:45-12:45	Roles and Responsibilities:	
	<ul style="list-style-type: none"> • Co-ordinator (10 min): IBEC. • Beneficiaries (10 min each): TUE, GRO, BAS, EDI, TAU, TEVA, TAG, BGX. • Partner organisations (5 min each): tbc. 	All
	Questions and doubts.	
12:45-13:30	Lunch.	
13:30-15:00	Project Management:	
	<ul style="list-style-type: none"> • General aspects. • Boards – Meetings – Web. • Recruitment. • Training Courses – Skill Modules - Secondments. 	IBEC (All)
	Questions and doubts.	
15:00-15:15	Tea and Coffee.	
15:15-18:00	Project Management:	
	<ul style="list-style-type: none"> • Dissemination and communication actions. • Milestones alignment and deliverables. • Reporting and Financial information. 	IBEC (All)
	Questions and doubts.	
18:00	AOB and Closing Remarks.	IBEC
20:00	Dinner*	



✓ D2.1: Meeting minutes
(Completed)

KICK-OFF MEETING

- IBEC (Barcelona, Spain): May 31st, 2018
- Attended by: PIs
- Agenda:

	Consortium Management	
10:00-10:30	Tea and Coffee.	
10:30-10:45	Roundtable introductions.	All
10:45-12:45	Roles and Responsibilities: <ul style="list-style-type: none"> • Co-ordinator (10 min): IBEC. • Beneficiaries (10 min each): TUE, GRO, BAS, EDI, TAU, TEVA, TAG, BGX. • Partner organisations (5 min each): tbc. Questions and doubts.	All
12:45-13:30	Lunch.	
13:30-15:00	Project Management: <ul style="list-style-type: none"> • General aspects. • Boards – Meetings – Web. • Recruitment. • Training Courses – Skill Modules - Secondments. Questions and doubts.	IBEC (All)
15:00-15:15	Tea and Coffee.	
15:15-18:00	Project Management: <ul style="list-style-type: none"> • Dissemination and communication actions. • Milestones alignment and deliverables. • Reporting and Financial information. Questions and doubts.	IBEC (All)
18:00	AOB and Closing Remarks.	IBEC
20:00	Dinner*	



✓ D2.1: Meeting minutes
(Completed)

SUPERVISORY BOARD: formed at kick-off meeting (D2.3)

- Composed by: Albertazzi (IBEC; Chair); Palmans (TU/e); Roelfes (GRO); Ward (BAS); Unciti-Broceta (EDI); Satchi-Fainaro (TAU); Avramovitch (TEVA); Robillard (TAG); Goldie (BGX) + Shreyas Wagle (TAU, ESRs Representative)
- Ultimate **decision-making body** of the project (**majority vote**), being responsible for implementing the project strategy
- This board will be responsible for:
 - ensuring **recruitment procedures** are open, transparent, and internationally comparable.
 - **overseeing the integration** of the fellows in the hosting institution and their mentoring.
 - ensuring that **scientific and technological training** through personalised research projects is balanced with **complementary skills training** to guarantee future ESR employability in all sectors.
 - monitoring the **implementation** of the research and training plan and solving any problem that may arise.
 - guaranteeing the **exchange of best practices** among partners.
 - providing uniform procedures to the Network through the elaboration and **approval of guidelines** for the elaboration of the PCDPs, the recruitment and assessment of ESRs, and the Strategy for dealing with scientific misconduct.

Supervisory Board Meetings: once a year (coinciding with Network Meetings)

RECRUITMENT COMMITTEE

- It is responsible for implementing the Recruitment Strategy.
- It is chaired by the coordinator (IBEC) and formed by:
 - Prof. Prats (UAB)
 - Prof. Ward (BAS)
 - Prof. Palmans (TU/e)

Consultant Board in case of conflicts (having on mind that each beneficiary is the main responsible of the recruitment process).

- This committee has been responsible for (IBEC has supervised all the actions):
 - Developing a recruitment plan defining the step by step process of employment.
Done (Recruitment Plan sent to all partners)
 - Ensuring gender balance within the recruitment.
Done (54% female ESRs)
 - Advertising positions internationally.
Done (all positions advertised in EURAXESS & other international webpages)
 - Dealing with any problem that may arise in the recruitment process.
Done (support provided to all partners whenever needed)

TRAINING COMMITTEE

- It is responsible for implementation of the Network based **training activities** and will care about the organisation of the Network wide training activities, the mediation in training related **conflicts**, **advising appropriate training directions**, and in the follow up of Doctoral Studies.
- It is chaired by Dr. Amir (TAU) and formed by:
 - Dr. Albertazzi (IBEC)
 - Dr. Goldie (BGX)
 - Prof. Roelfes (GRO)

Providing academic and industrial experience.
- This committee is responsible for:
 - defining the Network training activities.
 - evaluating the integration of the Network into local training programmes.
 - supervising and managing all the training activities.
 - supporting the definition of the Personal Career Development Plan (PCDP) for each ESR under the guidance of their supervisors outlining the individual learning objectives and skills to acquire throughout their doctoral/research training for their career development.

IP & INNOVATION COMMITTEE

- It is the body responsible for advising on **Intellectual Property and Innovation activities** related to the research developed within the project, with the support of the Tech Transfer departments of the members' institutions
- It is chaired by Dr. Avramovitch (TEVA) and formed by:
 - Dr. Robillard (TAG)
 - Dr. Unciti-Broceta (EDI)
 - Prof. Satchi-Fainaro (TAU)

Providing academic and industrial experience.

- This committee is responsible for:
 - periodic monitoring of the project scientific results, assessing the scientific achievements and progress.
 - determining whether some results are patentable.
 - investigating competitive landscapes and potential exploitation issues.

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

MEETING 1

- TUE (Eindhoven, The Netherlands): March 26th, 2019
- Attended by: PIs & ESRs
- Agenda:

Schedule	Activity	Responsible	Attendees
09:00-09:30	Tea and Coffee	-	All
09:30-09:45	Introduction of the network and meeting agenda	Albertazzi	All
09:45-12:15	Introduction of each PI and ESR: <ul style="list-style-type: none"> • PI (10 min/each) • ESR (3 min/each) Questions and doubts	All	All
12:15-13:15	Lunch (catering at ICMS)	-	All
13:15-15:00	Project Management: <ul style="list-style-type: none"> • General management issues • Boards • Recruitment • Training • Next meetings and events • Dissemination and communication actions • Deliverables and milestones alignment • Financial reporting information Questions and doubts	Miralles	Supervisory Board (PIs)
15:00-15:15	Tea and Coffee	-	All
15:15-16:30	Assessment Commissions (AC): <ul style="list-style-type: none"> • AC1 (Satchi-Fainaro, Roelfes, Avramovitch) for students ESR4, ESR5, ESR6, ESR10 • AC2 (Palmans, Unciti-Broceta, Robillard) for students ESR1, ESR2, ESR7, ESR9 • AC3 (Ward, Albertazzi, Goldie, Amir) for students ESR8, ESR11, ESR12, ESR13 	Turns of 3-4 PIs	ESRs
16:30	Closing Remarks	Albertazzi	All
19:00	Network Dinner at Eindhoven Stadbrouwerij. http://stadsbrouwerijeindhoven.com/index.php	-	#



✓ D2.4: Meeting minutes (Completed)

MEETING 1

- TUE (Eindhoven, The Netherlands): March 26th, 2019
- Attended by: PIs & ESRs
- Agenda:

Schedule	Activity	Responsible	Attendees
09:00-09:30	Tea and Coffee	-	All
09:30-09:45	Introduction of the network and meeting agenda	Albertazzi	All
09:45-12:15	Introduction of each PI and ESR: <ul style="list-style-type: none"> • PI (10 min/each) • ESR (3 min/each) Questions and doubts	All	All
12:15-13:15	Lunch (catering at ICMS)	-	All
13:15-15:00	Project Management: <ul style="list-style-type: none"> • General management issues • Boards • Recruitment • Training • Next meetings and events • Dissemination and communication actions • Deliverables and milestones alignment • Financial reporting information Questions and doubts	Miralles	Supervisory Board (PIs)
15:00-15:15	Tea and Coffee	-	All
15:15-16:30	Assessment Commissions (AC): <ul style="list-style-type: none"> • AC1 (Satchi-Fainaro, Roelfes, Avramovitch) for students ESR4, ESR5, ESR6, ESR10 • AC2 (Palmans, Unciti-Broceta, Robillard) for students ESR1, ESR2, ESR7, ESR9 • AC3 (Ward, Albertazzi, Goldie, Amir) for students ESR8, ESR11, ESR12, ESR13 	Turns of 3-4 PIs	ESRs
16:30	Closing Remarks	Albertazzi	All
19:00	Network Dinner at Eindhoven Stadtbrouwerij. http://stadsbrouwerijeindhoven.com/index.php	-	#



✓ D2.4: Meeting minutes (Completed)

ASSESSMENT COMMISSION


- Each ESR: AC composed of 3 members (partners with different profiles)
- ACs will meet with the ESR three times coinciding with Network Meetings 1, 2 and 3 to offer a broader perspective to the training and research being carried by the ESR

ESR / AC	<u>Assessment Commission 1</u>	<u>Assessment Commission 2</u>	<u>Assessment Commission 3</u>
	TAU-a (Satchi-Fainaro) GRO TEVA	TUE EDI TAG	BAS IBEC BGX TAU-b (Amir)
ESR1 (GRO)		X	
ESR2 (TAU-b; Amir)		X	
ESR3 (TEVA)			X
ESR4 (TUE)	X		
ESR5 (EDI)	X		
ESR6 (TUE; Albertazzi)	X		
ESR7 (IBEC)		X	
ESR8 (TUE)			X
ESR9 (BGX)		X	
ESR10 (BAS)	X		
ESR11 (EDI)			X
ESR12 (TAG)			X
ESR13 (TAU-a; Satchi-Fainaro)			X


AC: MEETING 1

- Integration of the ESR in the institution and THERACAT project, PCDP
- ✓ D7.3: Assessment Commission **(Completed)**


1. PhD enrolment **YES** / NO




2. Contractual difficulties/issues (YES / **NO**)




3. Integration within the host institution (BAD / REGULAR / **GOOD**)




4. Clear information about the project, network, etc. **YES** / NO



5. Local training meeting initial expectations (BELOW / **MEETS** / EXCEEDS EXPECTATIONS)



6. Personal Career Development Plan prepared **YES** / NO



✓ D7.1: PCDP
(Completed)

TRAINING EVENT 1:

Introducing the THERACAT Network & How to plan and start a PhD

- TUE (Eindhoven, The Netherlands): March 25th and 27-29th, 2019
- Attended by: ESRs & PIs involved
- Agenda:
 - Monday: General introduction
 - Wednesday: Skills to start a successful PhD
 - Thursday: Scientific communication
 - Friday: ESRs Meeting 1



TRAINING EVENT 1:

Introducing the THERACAT Network & How to plan and start a PhD

- TUE (Eindhoven, The Netherlands): March 25th and 27-29th, 2019
- Attended by: ESRs & PIs involved
- Agenda:
 - Monday: General introduction
 - Wednesday: Skills to start a successful PhD
 - Thursday: Scientific communication
 - Friday: ESRs Meeting 1



FELLOWS COMMITTEE

- Represents all the research fellows and is led by 3 ESRs each year, selected yearly by all ESRs by majority vote.
- Formed by:
 - Shreyas Wagle (TAU) – ESR Representative
 - Maria Vlastara (TAG)
 - Stephen Croke (EDI)
- Within this board ESRs:
 - discuss the network strategies and transfer to other relevant Committees when needed;
 - launch fellow-related initiatives;
 - supply inputs for the improvement of the programme (e.g. new training activities);
 - among others.

NEXT MEETINGS & EVENTS

Month	Date	Place	Duration	Meeting	Attendees
M01	May 31 st , 2018	IBEC	1 day	Kick-off Meeting	PIs
M12	March 25 – 29 th , 2019	TUE	1 day	Meeting 1	ESRs & PIs
			4 days	Training Event 1	ESRs & PIs involved
M16	June 5 th , 2019	EDI	1 day	Mid-Term Check Meeting with PO from EC	ESRs & PIs
M18	Sept. 23 – 27 th , 2019	BAS	5 days	Training Event 2	ESRs & PIs involved
M24	February 2020	EDI	1 ½ day	Meeting 2	ESRs & PIs
			5 days	Training Event 3	ESRs & PIs involved
M30	August 2020	TAU	5 days	Training Event 4	ESRs & PIs involved
M36	February 2021	IBEC	1 ½ day	Meeting 3	ESRs & PIs
			7 days	Training Event 5	ESRs & PIs involved
M42	August 2021	IBEC	1-2 days	THERACAT conference	ESRs & PIs
M48	February 2022	IBEC	1 ½ day	Final Meeting	ESRs & PIs

TRAINING PROGRAMME

1. Local Scientific Training activities, provided by host institutions:

- **By whom:** ESR's Supervisor/s & PhD program, post-doctoral staff
- **What:** All scientific, methodological and technical aspects relevant for the individual research project of the ESR and in which the host group is expert. Participation of ESRs in local training activities (e.g. seminars, complementary skills sessions, etc.)

2. THERACAT Conference: **Barcelona, August-September 2021**

- Lectures by the different PIs, ESRs and invited external experts
- Open also to non-member students (c.a. 50 students including THERACAT ESRs)
- Satellite of the NanoBio&Med conference in Barcelona

3. Secondments to other partner's laboratories:

- Takes place in an institution different from the host institution
- Between members of the network with complementary expertise and nature
- Fellows will be exposed to different disciplines and sectors (academic/industrial)

4. Network-wide scientific/complementary skills courses (Training Events, TE):

- Multidisciplinary content adapted to the different backgrounds of ESRs
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary
- TE may be open to PhD students from outside the network

TRAINING: Work already performed

Training Programme

1. Local scientific training activities: being implemented by all beneficiaries. **DONE**
2. THERACAT Conference: to be organised (2021)
3. Secondments: to be started
4. Training events:
 - TE1: Eindhoven (The Netherlands), March 25-29th, 2019. **DONE**
 - TE2: Basel (Switzerland), Sept. 23-27th, 2019

Other Training issues

- Doctoral Programme: all ESRs of the Network enrolled except ESR9. **DONE**
- Assessment Commission 1: Eindhoven (The Netherlands), March 26th, 2019. **DONE**
- Personal Career Development Plans (PCDP):
 - Ensemble of research objectives and training actions by ESRs
 - PCDP is a key instrument in the ESR professional development
 - Common structure, best practices and guidelines for the elaboration distributed to all partners
 - Prepared and agreed between the ESR and the Supervisor
 - Approved within 6 months after recruitment and updated yearly
- ✓ All ESRs' PCDP prepared → Deliverable 7.1. **(Completed)**

Date & Signature of supervisor



Bio-orthogonal catalysis for cancer therapy

Financial aspects

Mid-Term Check Meeting

Edinburgh, June 5th 2019

FINANCIAL ASPECTS

- A **maximum** grant amount is recorded in Grant Agreement (Article 5.1), Annex 2 and Consortium Agreement (considering redistribution of MGT budget): **€ 3.383.216,97**
- Funding mechanism based on units costs (**1 unit = 1 month of eligible ESR**). Thus, total costs are the number of units x unit costs.
- **Costs categories:**
 - A. Costs for Recruited Researchers:
 - A.1 Living allowance
 - A.2 Mobility allowance
 - A.3 Family allowance → ESR8 eligible (informed in RD)
 - B. Institutional Costs:
 - B.1 Research, training and networking costs
 - B.2 Management and indirect costs

Researcher			Institution	
<u>Living allowance*</u>	Mobility allowance	Family allowance	Research, training and networking costs	Management and indirect costs
<u>3 110</u>	600	500	1 800	1 200

*multiplied by the country correction coefficient



Bio-orthogonal catalysis for cancer therapy

Critical implementation risks and mitigation actions

Mid-Term Check Meeting

Edinburgh, June 5th 2019

MANAGEMENT RISKS

- **R1 (WP2):** One participant is not able to fulfil the plan of recruitment
ESR3 is the only student not incorporated yet despite being already selected and having his visa issued. Some measures had been taken to accelerate his incorporation such as involving Dr. Amir (TAU supervisor) in the process to mediate between TEVA and TAU, facilitating all paperwork and requirements from both beneficiaries.
- **R2 (WP2):** ESR not integrated in the host institution
No risks have been identified yet. Feedback received from all supervisors and ESRs suggests that a high-quality integration has been achieved for all ESRs.
- **R3 (WP2):** Partner leaving the project
No signs of this risk yet. The main modification concerning consortium beneficiaries has been the nomination of a new TEVA Scientist in Charge, Dr. Bianca Avramovitch, who replaced Dr. Hila Barash that was no longer working for the company due to the substantial internal restructuring process underwent at TEVA. This change was approved by the Project Officer through an amendment before being implemented.
- **R4 (WP2):** Cancellation of a planned secondment due to force majeure reasons
No risks have been identified yet. At the Network Meeting 1, the schedule of the secondments was readjusted taking into account the actual starting date of each ESR.
- **R5 (WP2):** Conflicts among partners, including IPR conflicts
No risks have been identified yet, with mitigation in part taking the form of a Consortium Agreement to set expectations of each partner. It will continue to be a key topic for the Coordinator and IP & Innovation Committee along the project.

SCIENTIFIC RISKS

- **R6 (WP3):** Delay in the synthesis of the materials in WP3
The timing of the recruitment will allow the synthesis of the first materials in time. The ESRs recruited for materials analysis and testing can start with testing their techniques on materials already available in the network (TAU, TUE, EDI).
- **R7 (WP4):** Delay in the prodrugs synthesis
Similarly some prodrugs and prodye are already available in the network (EDI, TUE) allowing the start of all projects.
- **R8 (WP5, WP6):** Technical issue with one imaging modality
No risks have been identified yet.
- **R9 (WP5, WP6):** Poor efficiency in biological tests in vitro and in vivo
No risks have been identified yet.



Bio-orthogonal catalysis for cancer therapy

Any proposed re-orientations of the networks' activities

Mid-Term Check Meeting

Edinburgh, June 5th 2019

Secondments: original plan (proposal submitted)

Months	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48		
ESR1												S	S	S										I	I	I																								
ESR2												S	S	S																																				
ESR3																		I	I	I	I									I	I	I	I	I																
ESR4																					S	S	S							I	I	I																		
ESR5																							I	I	I	I								S	S	S														
ESR6																							S	S	S													I	I	I										
ESR7																				I	I	I								S	S	S	S																	
ESR8																				S	S	S	S																											
ESR9																						S	S	S													I	I	I											
ESR10																												S	S	S								I	I	I										
ESR11																																																		
ESR12																		I	I	I								I	I							S	S	S												
ESR13																					S	S	S	S													I	I	I											

Secondments: current situation (after recruitment)

[illegible]

Secondments: original plan (proposal submitted)

Months	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48		
ESR1												S	S	S											I	I	I																							
ESR2												S	S	S																																				
ESR3																		I	I	I	I									I	I	I	I	I																
ESR4																					S	S	S							I	I	I																		
ESR5																								I	I	I	I							S	S	S														
ESR6																								S	S	S													I	I	I									
ESR7																					I	I	I							S	S	S	S																	
ESR8																					S	S	S	S																										
ESR9																																																		
ESR10																																																		
ESR11																																																		
ESR12																																																		
ESR13																																																		

Secondments: current situation (after recruitment)

Date	03/18				06/18						12/18		01/19								06/19								12/19		01/20						06/20						12/20		01/21						06/21						12/21		01/22	
Months	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48												
ESR1-GRO (M. Vargiu)																	S	S	S	S									I	I	I																													
ESR2-TAU (S. Wagle)																S	S	S																																										
ESR3-TEVA																																																												
ESR4-TUE (A. Sathyan)																																																												
ESR5-EDI (S. Croke)																																																												
ESR6-TUE (M. Arxontakis)																																																												
ESR7-IBEC (A. Olea)																																																												
ESR8-TUE (L. Deng)																																																												
ESR9-BGX (A. Galvez)																																																												
ESR10-BAS (B. Lozhkin)																																																												
ESR11-EDI (M. van de L'Isle)																																																												
ESR12-TAG (M. Vlastara)																																																												
ESR13-TAU (D. Rodriguez)																																																												

Some partners would like to re-schedule secondments to maximise scientific productivity – how to proceed?

MSCA-ITN-2017 – Innovative Training Networks



Bio-orthogonal catalysis for cancer therapy

Coordinator's report

Mid-Term Check Meeting

Edinburgh, June 5th 2019

